Category: Slow Trader Hedge Fund

We have a buy signal on IDH. One aspect of our buy signal is saying caution, however, worth taking some more of this share.

IDH have announced that they can enter the US market with their Direct Renin assay.

This is used to find the amount of active renin present in the blood. Results of the test are used to assist clinicians in the investigation of hypertension related disorders such as primary aldosteronism and renovascular hypertension. This is a fast and reliable alternative to existing manual methods, and a necessity when screening in extended hypertensive populations.

Hypertension is the third leading cause of death after malnutrition and diseases related to smoking. One in every three American adults have high blood pressure.

IDS first launched the automated Direct Renin immunoassay in Europe in June 2012.

This could be a good opportunity to top up with RMV shares. Buy back of own shares for RMV is in full swing over the next couple of months. 2013 was a good year for house price increases, particularly in London. However, January 2014 has seen a pause. RMV has excellent value potential in its share price and a recent dip might provide a buy opportunity. As yet, it is a little early on our indicators but a move back up could happen quickly. Be ready.

A good time to buy some more of AMS – At about £1.10. A medical technology company, selling advanced wound care products. They are debt free as of the end of 2013. Founding chairman of 16 years retired a few days ago. His replacement, Peter Allen (57), is external to AMS but experienced as a value creator within the health care industry. The global wound care market is worth $15 billion. The majority of sales by AMS come from their own brands. 450 employees. Products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in Czech Republic. A growing company with excellent value left in their share price.

We have sold FSJ. Based on last years figures, share price is nearly at value.

Here is a list of our shares posted to-date with percentage increase/decrease in price over the last 3-months:

I have been a supporter of Playtech since 2012. Since then there have only been 2 or 3 buy times. Now could be one of those times. A software developer for online gaming such as BET365. Most sales are from Europe followed by Asia. 3000 people are employed by Playtech throughout 12 countries.

Playtech sales, from their last report, are up and they say ‘we are confident of achieving our end of year expectations’.

Interest payments last year were high and their earnings growth saw a dip. Also, reported tax paid was low which could mean a higher tax bill next year. However, on the positive, they are a consistent and growing company that is short term debt free. They also showed a massive increase in profit at the half year point which could over ride any concerns. 

The share price dropped a lot this month but seems to be recovering up again.

Results out today and Aveva take an immediate 9% drop in share price. Revenue up slightly with little change in operating profit. A special divided of 100 million had been paid in the last 6 months. Maybe the drop was because the report was only good and not very good. However, the company is debt free, and growing. This could present a buying opportunity over the next few days. 

See 9 October entry for Tracsis.

End of year results (July 2013), released a week ago. Share price down from £2.10 to £1.88. Why did its share price drop? probably because Tracsis’s net profit was down from 34% last year to 23% this year. However, within the 23% was the purchase of Sky High in April 2013 – an Australian data capture company – for just over £3 million. Tracsis, however, have increased sales to just over £10 million a year, and, after the purchase of Sky High, Tracsis remain debt free. Sky High provide a bigger presence in Australia and Tracsis have recently increased sales in New Zealand. The Chairman and a director of Tracsis have stood down to allow ‘new faces to take them through the next phase of growth’ – the Director mentioned above remains with Tracsis part time. The points mentioned in early October still stand and with the recent drop in share price Tracsis is possibly an even better buy opportunity, but don’t delay!